BBIO vs. BMY: BridgeBio Pharma vs. Bristol-Myers Squibb Stock Comparison

Company Profile

BridgeBio Pharma (BBIO) and Bristol-Myers Squibb (BMY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BBIO is classified in Biotechnology while BMY is classified in Pharmaceuticals.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Capital efficiency shows on one side only: Bristol-Myers Squibb (BMY) earns 44.01% on shareholders’ equity, ranked against its industry; BridgeBio Pharma (BBIO) has no ROE this period.

BridgeBio Pharma (BBIO) reports a negative net margin of -59.84%, usually indicating a net loss over the period. Meanwhile Bristol-Myers Squibb (BMY) reports 18.47%, ranking against industry peers normally.

BridgeBio Pharma (BBIO) reports a negative operating margin of -3.30%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Bristol-Myers Squibb (BMY) reports 33.79%, ranking against industry peers normally.

Profitability Metrics

Growth

BridgeBio Pharma (BBIO) at 126.26% sits in the top revenue growth quartile, while Bristol-Myers Squibb (BMY) at -0.22% is closer to the peer norm — faster top-line expansion for BBIO.

Neither BridgeBio Pharma (BBIO) nor Bristol-Myers Squibb (BMY) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Financial Strength

Both BridgeBio Pharma (BBIO) at 2.09 and Bristol-Myers Squibb (BMY) at 1.59 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Only one side’s leverage can be read here: Bristol-Myers Squibb (BMY) carries debt-to-equity ratio of 1.91 against its industry range, while BridgeBio Pharma (BBIO) reports no figure this period.

Financial Strength Metrics

Dividends

BridgeBio Pharma (BBIO) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bristol-Myers Squibb (BMY) reports a yield of 3.99%, ranking against industry peers normally.

BridgeBio Pharma (BBIO) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bristol-Myers Squibb (BMY) reports a payout of 55.88%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Bristol-Myers Squibb (BMY) trades at 13.78 times trailing earnings, ranked against its peers, while BridgeBio Pharma (BBIO) has no P/E ratio this period.

Bristol-Myers Squibb (BMY) at 2.54 sits in the cheaper P/S ratio quartile while BridgeBio Pharma (BBIO) at 15.31 prices around its industry’s middle — BMY costs less per dollar of sales, though read it alongside growth and margins.

BridgeBio Pharma (BBIO) reports a negative P/B ratio of -5.59, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Bristol-Myers Squibb (BMY) reports 5.43, ranking against industry peers normally.

Valuation Metrics